Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.
Félix BalazardAurélie BertautÉlise BordetStéphane MulardJulie BlancNathalie BriotGautier PauxAsma Dhaini MerimecheOlivier RigalCharles CoutantMarion FournierChristelle JouannaudPatrick SoulieFlorence LereboursPaul-Henri CottuOlivier TrédanLaurence VanlemmensChristelle LevyMarie-Ange Mouret-ReynierMario CamponeKeri J S BradyMedha SasaneMegan RiceCatherine CoulouvratAnne-Laure MartinAlexandra JacquetInes Vaz LuisChristina HeroldBarbara PistilliPublished in: Journal of the National Cancer Institute (2023)
Tolerability and adherence to ET remains a challenge for patients who switch to a second ET. An early discontinuation model using patient-reported outcomes identifies patients likely to discontinue their adjuvant ET. Improved management of toxicities and novel more tolerable adjuvant ETs are needed for maintaining patients on treatment.